Qinlu Li, Shugang Xing, Heng Zhang, Xia Mao, Min Xiao, Ying Wang
{"title":"FISH与RT-PCR相结合,通过更好地识别ZNF384重排,有助于对中国成年B型其他ALL患者进行分类。","authors":"Qinlu Li, Shugang Xing, Heng Zhang, Xia Mao, Min Xiao, Ying Wang","doi":"10.1080/10428194.2024.2426055","DOIUrl":null,"url":null,"abstract":"<p><p>ZNF384 gene rearrangements are a distinct subtype of adult B cell acute lymphoblastic leukemia (B-ALL). We screened 46 B-other ALL patients for <i>ZNF384</i> fusions using fluorescent <i>in situ</i> hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR). Clinical data, treatment response, and minimal residual disease (MRD) status were analyzed. Ten (21.7%) patients were <i>ZNF384-r</i> positive (nine by FISH, nine by RT-PCR, eight by both<b>).</b> FISH showed atypical signals, including 3' signal gain and 5' signal deletion. <i>EP300</i> was the main fusion partner (<i>n</i> = 5). TAF15::ZNF384, SYNRG::ZNF384, CREBBP::ZNF384, and TCF3::ZNF384 fusions were found in one patient each; one case's partner gene is unknown. One patient was MRD-negative at the end of the first induction, lower than in patients without <i>ZNF384-</i>r. <i>ZNF384</i>-r incidence matched B-other ALL incidence in Chinese patients. Combined FISH and RT-PCR improved detection. ALL with <i>ZNF384</i>-r has unique features, and lower MRD-negative response may indicate a negative impact on traditional treatments.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"507-515"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of <i>ZNF384</i> rearrangement.\",\"authors\":\"Qinlu Li, Shugang Xing, Heng Zhang, Xia Mao, Min Xiao, Ying Wang\",\"doi\":\"10.1080/10428194.2024.2426055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ZNF384 gene rearrangements are a distinct subtype of adult B cell acute lymphoblastic leukemia (B-ALL). We screened 46 B-other ALL patients for <i>ZNF384</i> fusions using fluorescent <i>in situ</i> hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR). Clinical data, treatment response, and minimal residual disease (MRD) status were analyzed. Ten (21.7%) patients were <i>ZNF384-r</i> positive (nine by FISH, nine by RT-PCR, eight by both<b>).</b> FISH showed atypical signals, including 3' signal gain and 5' signal deletion. <i>EP300</i> was the main fusion partner (<i>n</i> = 5). TAF15::ZNF384, SYNRG::ZNF384, CREBBP::ZNF384, and TCF3::ZNF384 fusions were found in one patient each; one case's partner gene is unknown. One patient was MRD-negative at the end of the first induction, lower than in patients without <i>ZNF384-</i>r. <i>ZNF384</i>-r incidence matched B-other ALL incidence in Chinese patients. Combined FISH and RT-PCR improved detection. ALL with <i>ZNF384</i>-r has unique features, and lower MRD-negative response may indicate a negative impact on traditional treatments.</p>\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":\" \",\"pages\":\"507-515\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2024.2426055\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2426055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
ZNF384 基因重排是成人 B 细胞急性淋巴细胞白血病(B-ALL)的一个独特亚型。我们利用荧光原位杂交(FISH)和反转录聚合酶链反应(RT-PCR)对46例B型其他ALL患者进行了ZNF384融合的筛查。对临床数据、治疗反应和最小残留病(MRD)状态进行了分析。10例(21.7%)患者ZNF384-r阳性(FISH 9例,RT-PCR 9例,两者均8例)。FISH显示出非典型信号,包括3'信号增益和5'信号缺失。EP300 是主要的融合伙伴(n = 5)。TAF15::ZNF384、SYNRG::ZNF384、CREBBP::ZNF384和TCF3::ZNF384融合分别在一名患者中发现;其中一例患者的伴侣基因不明。一名患者在第一次诱导结束时MRD阴性,低于无ZNF384-r的患者。ZNF384-r的发病率与中国患者中B型其他ALL的发病率相符。FISH和RT-PCR联合检测可提高检测率。带有ZNF384-r的ALL有其独特性,较低的MRD阴性反应可能预示着对传统治疗方法的负面影响。
FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.
ZNF384 gene rearrangements are a distinct subtype of adult B cell acute lymphoblastic leukemia (B-ALL). We screened 46 B-other ALL patients for ZNF384 fusions using fluorescent in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR). Clinical data, treatment response, and minimal residual disease (MRD) status were analyzed. Ten (21.7%) patients were ZNF384-r positive (nine by FISH, nine by RT-PCR, eight by both). FISH showed atypical signals, including 3' signal gain and 5' signal deletion. EP300 was the main fusion partner (n = 5). TAF15::ZNF384, SYNRG::ZNF384, CREBBP::ZNF384, and TCF3::ZNF384 fusions were found in one patient each; one case's partner gene is unknown. One patient was MRD-negative at the end of the first induction, lower than in patients without ZNF384-r. ZNF384-r incidence matched B-other ALL incidence in Chinese patients. Combined FISH and RT-PCR improved detection. ALL with ZNF384-r has unique features, and lower MRD-negative response may indicate a negative impact on traditional treatments.
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor